Fibroheal Woundcare, an innovative startup that is pioneering the use of Silk proteins for wound care, has successfully raised Rs 6.3 crore in a pre-Series A funding round. This significant investment is expected to accelerate the company’s growth and bring cutting-edge wound management solutions to more hospitals and patients across India. Fibroheal’s unique approach to wound care, using bioactive Silk proteins, promises to improve the healing process for a range of complex and chronic wounds. Here’s everything you need to know about the startup, its groundbreaking products, and its ambitious plans for the future.
What is Fibroheal Woundcare?
Founded in April 2017 by Vivek Mishra, Bharat Tandon, and S Subramanian, Fibroheal Woundcare is making strides in the medical device industry. The company specializes in the development of Silk protein-based products that help treat a variety of difficult-to-heal wounds. These include diabetic ulcers, post-operative wounds, bed sores, traumatic injuries, and more.
Silk protein, known for its unique healing properties, forms the foundation of the company’s products. Fibroheal’s products are designed to promote faster healing by providing a natural, biocompatible material that accelerates tissue regeneration.
Why is Silk Protein So Special?
Silk, long known for its luxurious feel, is now being recognized for its powerful healing properties. Silk proteins are naturally anti-inflammatory, promote collagen formation, and help speed up wound recovery. The use of Silk in medical devices is relatively new, and Fibroheal has become the first company in India to bring this innovative technology to market.
The company’s research into Silk proteins has already yielded several patents, and it is continuing to innovate. With this new funding, Fibroheal aims to expand its product offerings and make these life-changing treatments accessible to more people.
Fibroheal’s Product Line
Fibroheal offers a wide range of medical devices aimed at addressing various stages of wound healing. Some of the products in its portfolio include:
- Foams: Used for dressing wounds, these foams absorb exudates and protect the wound from infection.
- Mesh: A breathable material that helps protect wounds while allowing them to heal.
- Adhesive Dressings: Convenient and easy-to-apply dressings for day-to-day wound care.
- Sprays and Gels: For easy application on wounds, these sprays and gels create a protective layer over the affected area.
These products are already making a significant impact. Fibroheal claims that their medical devices are currently being used in over 500 hospitals across India, spanning 19 states.
How Will the Rs 6.3 Crore Investment Be Used?
Fibroheal’s recent fundraising round was supported by a mix of existing and new investors, including prominent surgeons, medical professionals, and bankers. The Rs 6.3 crore will be used to scale the company’s operations, expand its product range, and recruit more talented professionals to join the team.
In addition to this, Fibroheal has already received a commitment for another Rs 10 crore in funding, which will help further strengthen the company’s market presence. With these funds, Fibroheal plans to:
- Expand its product pipeline, focusing on future innovations in medical devices and biomaterials.
- Increase its marketing efforts to introduce Silk protein-based solutions to more hospitals and healthcare providers.
- Enhance its research and development efforts, ensuring that Fibroheal continues to lead the field of advanced wound care.
A Team with Vision and Expertise
Fibroheal’s founders bring years of expertise in the healthcare and medical device industries. Vivek Mishra and Bharat Tandon co-founded the company with the vision of creating high-quality, cost-effective wound care solutions. In 2018, S Subramanian joined the team as a co-promoter, bringing additional experience in business development and operations.
What sets Fibroheal apart is its focus on research and development. The startup has already secured 8+ patents and is working on several more. It has also collaborated with the Indian Institute of Science (IISc) in Bangalore, resulting in the successful development of an external haemostatic product called “Fibroplug.”
The Future of Fibroheal Woundcare
With the recent investment, Fibroheal is poised for significant growth. The company plans to expand its reach, not just within India but also internationally. By leveraging Silk proteins and other biomaterials, Fibroheal aims to revolutionize the wound care industry and improve the lives of millions of patients suffering from chronic and difficult-to-heal wounds.
Conclusion
Fibroheal is on a mission to change the way we approach wound care. By tapping into the unique healing properties of Silk proteins, the startup is developing advanced medical devices that are already making a real difference in the lives of patients. With the new funding, a strong product pipeline, and a team dedicated to innovation, Fibroheal is well on its way to becoming a leader in the global medical device market.
As they continue to grow and expand, we can expect even more groundbreaking products from Fibroheal that will help doctors, surgeons, and patients alike navigate the challenges of wound management. The future of wound care is here—and it’s powered by Silk.